ZIOPHARM Oncology Inc (NASDAQ:ZIOP) CEO Laurence James Neil Cooper acquired 6,440 shares of the stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the purchase, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) traded down $0.25 during mid-day trading on Friday, reaching $4.30. The company had a trading volume of 3,309,900 shares, compared to its average volume of 1,654,172. ZIOPHARM Oncology Inc has a 52-week low of $4.16 and a 52-week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. analysts predict that ZIOPHARM Oncology Inc will post -0.54 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/insider-buying-ziopharm-oncology-inc-ziop-ceo-purchases-30139-20-in-stock.html.
Several research analysts recently commented on ZIOP shares. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright set a $10.00 target price on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Friday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $12.58.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of ZIOPHARM Oncology by 7.6% during the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after acquiring an additional 553,933 shares during the period. State Street Corp lifted its holdings in shares of ZIOPHARM Oncology by 12.8% during the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after acquiring an additional 517,057 shares during the period. Morgan Stanley lifted its holdings in shares of ZIOPHARM Oncology by 19.5% during the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after acquiring an additional 324,774 shares during the period. Northern Trust Corp lifted its holdings in shares of ZIOPHARM Oncology by 10.1% during the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after acquiring an additional 149,067 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of ZIOPHARM Oncology by 3.9% during the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock valued at $6,444,000 after acquiring an additional 38,173 shares during the period. 41.86% of the stock is owned by institutional investors.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.